260 related articles for article (PubMed ID: 30473361)
1. Drug screening assay based on the interaction of intact Keap1 and Nrf2 proteins in cancer cells.
Zhou B; Zhang X; Wang G; Barbour KW; Berger FG; Wang Q
Bioorg Med Chem; 2019 Jan; 27(1):92-99. PubMed ID: 30473361
[TBL] [Abstract][Full Text] [Related]
2. Measuring Changes in Keap1-Nrf2 Protein Complex Conformation in Individual Cells by FLIM-FRET.
Dikovskaya D; Dinkova-Kostova AT
Curr Protoc Toxicol; 2020 Sep; 85(1):e96. PubMed ID: 32786061
[TBL] [Abstract][Full Text] [Related]
3. Diffusion dynamics of the Keap1-Cullin3 interaction in single live cells.
Baird L; Dinkova-Kostova AT
Biochem Biophys Res Commun; 2013 Mar; 433(1):58-65. PubMed ID: 23454126
[TBL] [Abstract][Full Text] [Related]
4. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
Lee S; Abed DA; Beamer LJ; Hu L
SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
[TBL] [Abstract][Full Text] [Related]
5. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy.
Yoshizaki Y; Mori T; Ishigami-Yuasa M; Kikuchi E; Takahashi D; Zeniya M; Nomura N; Mori Y; Araki Y; Ando F; Mandai S; Kasagi Y; Arai Y; Sasaki E; Yoshida S; Kagechika H; Rai T; Uchida S; Sohara E
Sci Rep; 2017 Jun; 7(1):3945. PubMed ID: 28638054
[TBL] [Abstract][Full Text] [Related]
6. Measuring the Interaction of Transcription Factor Nrf2 with Its Negative Regulator Keap1 in Single Live Cells by an Improved FRET/FLIM Analysis.
Dikovskaya D; Appleton PL; Bento-Pereira C; Dinkova-Kostova AT
Chem Res Toxicol; 2019 Mar; 32(3):500-512. PubMed ID: 30793592
[TBL] [Abstract][Full Text] [Related]
7. A Naturally-Occurring Dominant-Negative Inhibitor of Keap1 Competitively against Its Negative Regulation of Nrf2.
Qiu L; Wang M; Zhu Y; Xiang Y; Zhang Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042301
[TBL] [Abstract][Full Text] [Related]
8. Development of a High-Throughput Cul3-Keap1 Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for Identifying Nrf2 Activators.
Poore DD; Hofmann G; Wolfe LA; Qi H; Jiang M; Fischer M; Wu Z; Sweitzer TD; Chakravorty S; Donovan B; Li H
SLAS Discov; 2019 Feb; 24(2):175-189. PubMed ID: 30383469
[TBL] [Abstract][Full Text] [Related]
9. Absolute Amounts and Status of the Nrf2-Keap1-Cul3 Complex within Cells.
Iso T; Suzuki T; Baird L; Yamamoto M
Mol Cell Biol; 2016 Dec; 36(24):3100-3112. PubMed ID: 27697860
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K; Motohashi H; Yamamoto M
Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
[TBL] [Abstract][Full Text] [Related]
11. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex.
Zhang DD; Lo SC; Cross JV; Templeton DJ; Hannink M
Mol Cell Biol; 2004 Dec; 24(24):10941-53. PubMed ID: 15572695
[TBL] [Abstract][Full Text] [Related]
12. Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.
Schaap M; Hancock R; Wilderspin A; Wells G
Protein Sci; 2013 Dec; 22(12):1812-9. PubMed ID: 24130096
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
14. Protocol for a Steady-State FRET Assay in Cancer Chemoprevention.
Schaap MC; Guimarães AM; Wilderspin AF; Wells G
Methods Mol Biol; 2016; 1379():165-79. PubMed ID: 26608299
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2.
Kobayashi A; Kang MI; Okawa H; Ohtsuji M; Zenke Y; Chiba T; Igarashi K; Yamamoto M
Mol Cell Biol; 2004 Aug; 24(16):7130-9. PubMed ID: 15282312
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
18. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
19. Structural and biochemical characterization establishes a detailed understanding of KEAP1-CUL3 complex assembly.
Adamson RJ; Payne NC; Bartual SG; Mazitschek R; Bullock AN
Free Radic Biol Med; 2023 Aug; 204():215-225. PubMed ID: 37156295
[TBL] [Abstract][Full Text] [Related]
20. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
